{
  "ptid_time": "002_S_1261_2014-03-13",
  "img_path": "/data/qiuhui/data/adni/images/002_S_1261/2014-03-13/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 46,473 mm³, 65.6% above the reference mean. With a Z-score of 1.50 (93.3th percentile), this represents moderate enlargement; hippocampal volume measures 5,269 mm³, 25.9% below the reference mean. With a Z-score of -2.38 (0.9th percentile), this represents significant atrophy; whole brain volume measures 1,021,500 mm³, 4.8% above the reference mean. With a Z-score of 0.61 (72.7th percentile), this represents normal volume ; entorhinal cortex volume measures 2,327 mm³, 36.6% below the reference mean. With a Z-score of -2.25 (1.2th percentile), this represents significant atrophy; fusiform gyrus volume measures 15,946 mm³, 6.3% below the reference mean. With a Z-score of -0.57 (28.4th percentile), this represents normal volume ; middle temporal gyrus volume measures 19,004 mm³, 0.9% below the reference mean. With a Z-score of -0.07 (47.0th percentile), this represents normal volume . ",
  "text_data": "Age is 78.1 years. Gender is Female. Education: 16 years. MMSE: 30.0. MoCA: 24.0. Logical Memory: 14.0. APOEε4 alleles: 0.0. ",
  "true_diagnosis": "Diagnosis: CN.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows significant atrophy in the hippocampus and entorhinal cortex, both critical regions for memory and early Alzheimer's pathology, while ventricular enlargement suggests underlying neurodegeneration. Despite normal MMSE (30/30), the MoCA (24/30) indicates subtle cognitive deficits, which, combined with the structural changes, suggest early cognitive impairment. The absence of APOE4 reduces genetic risk but does not rule out sporadic Alzheimer's.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely amnestic subtype given hippocampal/entorhinal atrophy).  \n\n**Confidence:** **Medium** (high confidence in neurodegeneration based on imaging, but MCI diagnosis is provisional without longitudinal cognitive decline or biomarker confirmation of Alzheimer’s pathology).  \n\n**Note:** A follow-up clinical assessment focusing on episodic memory and biomarkers (e.g., CSF Aβ/tau or PET) would strengthen diagnostic certainty. The discordance between MMSE (insensitive to early MCI) and MoCA (more sensitive) underscores the need for detailed neuropsychological testing.",
  "timestamp": "2025-07-25T20:13:49.316137"
}